About AVT
AVT is China’s premier vaccine adjuvant supplier. Leveraging our proprietary whole-plant extraction platform and proven industrial-scale manufacturing capabilities, we become the first company worldwide to achieve regulatory filing of QS-21 in both US FDA and China NMPA CDE. Our high-purity adjuvants are positioned for both human vaccines (e.g., herpes zoster, malaria, and cancer vaccines) and veterinary vaccines (where QS-ANM is a drop-in replacement for Quil-A®). Through a comprehensive technology-transfer package covering process, QC, and regulatory support, we empower partners to accelerate local deployment.
Why Partner with AVT?
✅ Technical barrier: Proprietary whole-plant extraction platform delivering superior cost-of-goods and purity;
✅ Global enablement: Regional price protection + go-to-market (GTM) programs + tailored regulatory services;
✅ Turn-key solution: End-to-end transfer from raw material to submission-ready dossier.
Ideal Partner Profiles
✔ Multinational companies or overseas local companies preferred;
✔ Proven track record of years promoting relevant products in the target market preferred;
✔ Deep familiarity with local regulatory requirements and commercial models, plus end-user access;
✔ Dedicated local team capable of independent customer acquisition and channel management;
✔ Sharp market insight and strong cross-cultural collaboration skills.
Partnership Scopes
Develop and execute regional market-entry strategies (online/offline promotional activities);
Continuously monitor market dynamics and competitive intelligence to refine tactics;
Align with AVT technical teams to deliver regulatory and technical support to clients.
Partner with AVT to tap into a multi-billion-dollar vaccine adjuvant opportunity together!
Contact: Emily Cao
Email: sales@avt-cn.com
Phone: +86 15251769003
www.avt-pharma.com
AVT Pharmaceutical
